{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACU-026-001-1",
    "query": {
      "intervention": "ACU-026-001-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T20:49:34.993Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06267872",
      "title": "A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "CD4BS CH505M5 Pr-NP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505TF chTrimer",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF (labeled as AP 60-702)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum Hydroxide Suspension (Alum)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACU-026-001-1 (labeled as empty LNP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-10-07",
      "completion_date": "2026-09-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-09-01T20:49:34.993Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06267872"
    },
    {
      "nct_id": "NCT07757802",
      "title": "Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "DV901-NP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DV902-NP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505 TF mRNA-gp160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505 w24 mRNA-gp160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACU-026-001-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2026-09-10",
      "completion_date": "2028-10-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-01T20:49:34.993Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07757802"
    },
    {
      "nct_id": "NCT05903339",
      "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "V3G CH848 Pr-NP1 60mcg",
          "type": "DRUG"
        },
        {
          "name": "3M-052-AF 5mcg",
          "type": "DRUG"
        },
        {
          "name": "Alum 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "V3G CH848 mRNA-Tr2 50mcg",
          "type": "DRUG"
        },
        {
          "name": "ACU-026-001-1 2.0mg",
          "type": "DRUG"
        },
        {
          "name": "V3G CH848 Pr-NP1 100mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2023-08-29",
      "completion_date": "2026-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-01T20:49:34.993Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05903339"
    }
  ]
}